The FTC Has the Chance to Rein in Big Pharma

Federal Trade Commission needs to keep a watchful eye on Big Pharma’s recent maneuvers to control necessary medicine.

Lilly and Novo Nordisk control almost the total supply of GLP-1 medications.

Lilly 's recent deals with telemedicine providers raise the specter of anticompetitive behavior.

As FTC Commissioner Mark Meador observed, there is an expressed “need for continued vigilance over competition in the healthcare space.” The FTC opening up an investigation into Lilly and Novo Nordisk’s practices would be precisely that..